₹330 per share in an otherwise weak market. "The development of an anti-viral APl 'MOLNUPIRAVIR' an additional COVID -19 treatment drug that is being developed at Lab Scale for the first-line treatment of COVID-19 in adults patients with mild to moderate symptoms," the company said in an exchange filing.
Everest Organics has joined Divi's Laboratories as an API maker for Merck's experimental oral drug. Merck recently sought US emergency use authorisation for the drug, putting molnupiravir on course to become the first oral antiviral medication for COVID-19.
Srikakarlapudi Sirisha, Chief Executive Officer, EOL - New Product Development said that “After the successful development and commercialization of various COVID-19 drugs, such as